-
Published 1/21/2026
Alsina M, Shah N, Jagannath S, Kaufman JL, Siegel D, Munshi NC, Rosenblatt J, Lin Y, Jakubowiak AJ, Derman BA, Li A, Mao P, Fincker M, Yeri A, Martin N, Campbell TB, Finney O, Truppel-Hartmann A, Petrocca F, Berdeja JG, Raje N. Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 study. Cancer Immunol Res. 2026 Jan 21. PMID: 41562447.
-
Published 9/3/2025
Ferri GM, Frank A, Li D, Anand P, Abdallah M, Avalone V, Mark Sloan J, Sanchorawala V, Lerner A, Szalat RE, Petrocca F, Edwards CV, Bell BN. When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e77-e82. PMID: 41015712.
-
Published 12/10/2024
Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
-
Published 8/17/2023
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023 Sep; 29(9):2286-2294. PMID: 37592106.
-
Published 2/25/2021
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716. PMID: 33626253.